A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour

Solid Tumors Clinical Trial

Official title:

A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00778128
• Other study ID #: CP4126-111
• Status: Completed
• Phase: Phase 1
• First received: October 22, 2008
• Last updated: September 3, 2010
• Start date: October 2008
• Est. completion date: April 2010

Study information

• Verified date: September 2010
• Source: Clavis Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
• Study type: Interventional

Clinical Trial Summary

At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will be randomized. They will receive at days 1 and 8 in a double cross design either oral CP-4126 at the recommended dose or gemcitabine 1000mg/m2 intravenously. At both steps, the schedule of treatment will be day 1, 8, 15 q4w until complete response or disease worsening/ progressing. All further treatment at step 2 will be oral CP-4126.

Description:

This is a multicentre clinical study conducted in Belgium and in The Netherlands. The study is a phase I divided in 2 steps: The first step is a dose escalation to define the RD. At the second step the PK profile of oral CP-4126 will be compared with the PK profile of IV gemcitabine. In addition, the study is conducted to characterize the tolerability of oral CP-4126, to evaluate its bioavailability, and to make a preliminary assessment of antitumor activity in patients with solid tumours.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically confirmed solid tumour diagnosis

2. Locally advanced or metastatic disease, for which there is no known effective treatment

3. Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status

4. Age 18 years or more

5. Life expectancy > 3 months

6. Adequate hematological and biological functions:

7. Signed informed consent

Exclusion Criteria:

1. Symptomatic brain metastases

2. Current peripheral neuropathy of grade > 1 according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

3. Radiotherapy

• to more than 30 % of bone marrow

• single dose up to 8 Gy

• less than one week prior to the study treatment

• of the upper GI tract

4. Mucositis of the upper digestive tract, including stomatitis

5. Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study

6. Previous anticancer therapy (chemotherapy, hormone therapy or immunotherapy) within 30 days prior to the first dose of oral CP-4126 [6 weeks for mitomycin C and BCNU (= carmustine) and CCNU (=lomustine)]

7. Requirement of concomitant treatment with a non-permitted medication including alternative drugs and high doses of vitamins

8. History of allergic reactions to gemcitabine

9. Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection)

10. Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance

11. Pregnant or breast feeding women

12. Absence of adequate contraception for both male and female fertile patients for the duration of the study; and also for six months after last treatment

13. Known positive status for HIV and/or hepatitis B or C

14. Any reason why, in the investigator's opinion, the patient should not participate

15. Condition that impairs ability to swallow pills

16. Coeliac disease or any other lipid malabsorption syndrome

17. Drug and/or alcohol abuse

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• CP-4126
Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
• Gemcitabine
Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression

Locations

Country	Name	City	State
Belgium	Institute Jules Bordet	Brussels
Netherlands	The Netherlands Cancer Institute	Amsterdam
Netherlands	University Medical Centre Utrecht	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
Clavis Pharma

Countries where clinical trial is conducted

Belgium,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Step 1: MTD of oral CP-4126 in patients with advanced solid tumours, followed by establishing the recommended dose		6 months	No
Primary	Step 2: Pharmacokinetic parameters comparison of oral CP-4126 with IV gemcitabine		12 months	No
Secondary	Tolerability of oral CP-4126		12 months	Yes
Secondary	Biovailability of oral CP-4126		12 months	No
Secondary	Preliminary assessment of antitumor activity of oral CP-4126		18 months	No